Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by canadapieton Mar 29, 2022 2:46am
49 Views
Post# 34554337

RE:RE:RE:RE:RE:One good decision TH could make right away

RE:RE:RE:RE:RE:One good decision TH could make right away
RE:RE:RE:RE:One good decision TH could make right away
Those fundamendantly sound reasons already exist (solid base revenues from the legacy drugs, strong balance sheet with ability to finance future growth from the markets and and a huge upside potential in cancer) but the current low share price is preventing buyers from buying the stock. A reverse split would be additive in TH's case and if you think otherwise, you are just not aware of those restrictions investors like myself and many others face that prevent and/or limit the ability to buy the stock. 

There are also issues with remaining on NASDAQ with a low priced stock but that is far away at the moment.

A reverse split is as meaningless as a normal stock split. It is just math. There are fewer shares and a higher share price. Fears of reverses stock splits based on the bad experiences with bad companies that dd them just do not apply to TH.
<< Previous
Bullboard Posts
Next >>